Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note issued to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $30.00 price objective on the stock. HC Wainwright also issued estimates for Voyager Therapeutics’ Q3 2024 earnings at ($0.31) EPS, Q4 2024 earnings at ($0.29) EPS, FY2024 earnings at ($0.97) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.20) EPS.

VYGR has been the topic of a number of other research reports. Wedbush dropped their price objective on Voyager Therapeutics from $8.00 to $7.00 and set a neutral rating on the stock in a research report on Wednesday, August 7th. Oppenheimer restated an outperform rating and issued a $18.00 price target on shares of Voyager Therapeutics in a report on Wednesday, May 15th. Finally, StockNews.com lowered shares of Voyager Therapeutics from a buy rating to a hold rating in a research note on Monday, May 13th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Voyager Therapeutics currently has an average rating of Moderate Buy and a consensus price target of $17.83.

Voyager Therapeutics Stock Performance

NASDAQ VYGR opened at $6.80 on Tuesday. The company has a market cap of $369.88 million, a PE ratio of -136.00 and a beta of 0.96. The firm’s 50 day moving average price is $7.94 and its 200-day moving average price is $8.33. Voyager Therapeutics has a 52-week low of $6.06 and a 52-week high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. The company had revenue of $29.58 million during the quarter, compared to analyst estimates of $11.52 million. During the same quarter in the prior year, the business earned ($0.51) earnings per share. On average, analysts forecast that Voyager Therapeutics will post -1.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Voyager Therapeutics

Large investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company raised its position in shares of Voyager Therapeutics by 6.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 94,398 shares of the company’s stock valued at $747,000 after purchasing an additional 5,365 shares during the last quarter. Armistice Capital LLC raised its holdings in shares of Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after buying an additional 528,000 shares during the last quarter. Great Point Partners LLC acquired a new stake in shares of Voyager Therapeutics during the second quarter worth $12,668,000. Hsbc Holdings PLC purchased a new stake in shares of Voyager Therapeutics during the second quarter valued at $128,000. Finally, Massachusetts Financial Services Co. MA increased its position in shares of Voyager Therapeutics by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 143,523 shares of the company’s stock valued at $1,135,000 after acquiring an additional 4,816 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.